Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 21,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Non-Hodgkin's Lymphoma, Burkitt Lymphoma, Primary Effusion Lymphomas
Interventions: Pegylated Liposomal Doxorubicin (Doxil) and Rituximab; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions: Resmetirom, Placebo Control; Drug
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more

Conditions: Mantle Cell Lymphoma
Interventions: P276-00; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota + 9 more

Conditions: Neonatal Screening, Kernicterus, Newborn Jaundice, Point-of-Care Testing
Interventions: Bilistick System 2.0 point-of-care testing device; Diagnostic Test
Lead sponsor: Kettering Health Network; Other
Eligibility: Up to 2 Weeks
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: GVHD
Interventions: Apraglutide; Drug
Lead sponsor: VectivBio AG; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Stanford, California • Iowa City, Iowa • Boston, Massachusetts + 2 more

Conditions: B-Cell Chronic Lymphocytic Leukemia
Interventions: bafetinib; Drug
Lead sponsor: CytRx; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Duarte, California • Houston, Texas

Conditions: Type 1 Diabetes
Interventions: Closed-loop; Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma
Interventions: Insulin Glargine, Insulin Aspart; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Microtia, Dysbiosis, Alcohol Drinking, HIV Infections, Cardiovascular Diseases
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Phoenix, Arizona • Bryant, Arkansas • Huntington Beach, California + 16 more

Conditions: Multiple Sclerosis
Interventions: Body-weight supported treadmill, Lokomat; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infection
Interventions: Nutropin, Oral Glucose Tolerance Test, Dual Energy X-ray Absorptiometry (DEXA), Computed Tomography (CT) Scan; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Dallas, Texas

Conditions: Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: HIV/AIDS, Gonorrhea, Chlamydia
Interventions: Keep It Up! 3.0; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 2,249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: CVD908ssb-TXSVN; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: Structured Ecosystems Therapy (SET), Individually tailored intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Peer-assisted asthma self-management program, Adult-led asthma self-management program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 13 Years to 20 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Graft-versus-host-disease
Interventions: Axatilimab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 37 more

Conditions: Mantle Cell Lymphoma
Interventions: Panobinostat, Bortezomib; Drug
Lead sponsor: Anand Jillella; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Lymphoma
Interventions: Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Gilbert, Arizona • Campbell, California • Duarte, California + 29 more

Conditions: Opiate Dependence, HIV Infections
Interventions: Buprenorphine/Subutex, Naltrexone, Drug counseling; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumors, Lymphoma
Interventions: Ulevostinag, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more

Conditions: Neuralgia, Postherpetic
Interventions: Lamictal in the treatment of Post-Herpetic Neuralgia; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 85 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Bilistick Point-of-care System 2.0 Bilirubin Validation

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Restoration of Walking in Multiple Sclerosis Using Treadmill Training.

The Use of Nutropin Depot in HIV-infected Adult Males

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0)

Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine

Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Teen Asthma Project

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

HIV Risk Reduction and Drug Abuse Treatment in Iran

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lamictal in the Treatment of Post-Herpetic Neuralgia